One (1) warrant of series TO4B is granted for 27 existing shares held by the shareholder on the record date 30th May 2018, rounded downwards.

Each warrant entitles the holder to subscribe for one (1) new Episurf share at a fixed strike price of SEK 6.10 during the periods below.

Subscription of new shares through the exercise of warrants of series TO4B for a total value of SEK 500,000 or more may take place from the registration date of the decision to issue the warrants at the Swedish Companies Registration Office until the last day of five (5) years after the registration date at the Swedish Companies Registration Office. The issue of warrants of series TO4B was registered at the Swedish Companies Registration Office on Wednesday, 23rd May  2018.

The exercise of warrants below an aggregated amount of SEK 500,000 may take place on ten occasions during the two-week period preceding the day of 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60 months after the date on which the warrants are registered at the Swedish Companies Registration Office, 23 May 2018. Subscription of shares based on warrants of series TO4B will subsequently be possible during the following periods:

– Thursday, May 9, 2019 until Thursday, May 23, 2019
– Saturday November 9, 2019 until Saturday, November 23, 2019
– Saturday, May 9, 2020 until Saturday, May 23, 2020
– Monday, November 9, 2020 until Monday, November 23, 2020
– Sunday, May 9, 2021 until Sunday, May 23, 2021
– Tuesday, November 9, 2021 until Tuesday, November 23, 2021
– Monday, May 9, 2022 until Monday, May 23, 2022
– Wednesday November 9, 2022 until Wednesday, November 23, 2022
– Tuesday, May 9, 2023 until Tuesday, May 23, 2023
– Thursday, November 9, 2023 until Thursday, November 23, 2023

The warrants are available from 2018-06-01. This is executed automatically via Euroclear, which manages the company’s share register.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel:+46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.